Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
CYP Stock Chart & Stats
AU$0.29
-AU$0.01(-4.17%)
At close: 4:00 PM EST
AU$0.29
-AU$0.01(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.14 - AU$0.44
Previous CloseN/A
Volume63.41K
Average Volume (3M)233.82K
Market Cap
AU$89.05M
Enterprise ValueAU$80.43M
Total Cash (Recent Filing)AU$5.05M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding237,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt materially reduces financial risk and preserves strategic optionality for a clinical-stage biotech. Over 2–6 months this improves the company's ability to fund development via equity or partnerships, lowers bankruptcy risk, and makes it a more attractive collaborator for licensors.
High Gross MarginsNear-100% gross margins indicate attractive unit economics for cell therapy manufacturing and licensing. Once development and regulatory hurdles are cleared, high margins can support scalable royalties or product sales, enabling durable profitability if fixed R&D and SG&A are controlled.
Proprietary Allogeneic PlatformCymerus's iPSC‑derived allogeneic MSC approach is structurally scalable relative to autologous therapies. A platform that can address multiple immune/inflammatory indications supports licensing opportunities, recurring royalty streams and strategic partnerships, a durable commercial pathway.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow forces reliance on external funding. Over months this elevates dilution risk, can constrain trial progress, and increases execution risk if capital markets or partner interest weaken, threatening program timelines.
Large Operating LossesMeaningful operating losses and negative net margins reflect that current revenues are insufficient to cover R&D and SG&A. Structural improvement requires either successful commercialization or significant partnership deals; absent those, losses will continue to erode equity over time.
No Commercial Revenue / Partnership DependenceBusiness economics are binary: value depends on deals or regulatory approval. Dependence on future partnerships or successful commercialization creates concentrated execution and regulatory risk, making medium-term cashflows uncertain and outcomes highly dependent on third parties.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.43 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$89.05M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 191 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 237,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYP Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-138.54%
Trailing 12-Months
Asset Growth
-15.80%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).
Technical Analysis
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
Options Prices
Currently, No data available
---